Search - tctmd.com

Displaying 301 - 320 of 1259

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Scott Lim

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Presenter: John G. Webb, Ajit Yoganathan, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

The TAVR Development Journey: Lessons Learned and Drivers of Success

Presenter: John G. Webb, Ajit Yoganathan

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies II: Updates From SURTAVI

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Presenter: Felix Mahfoud, Michael A. Weber, Michael Joner

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Presenter: Schuyler Jones, Misti Malone, Eleni Whatley

October 30, 2016

Advertisement

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Flash Debate: Point Surgical Risk Stratification for TAVR Should Be Replaced by Anatomic and Clinical Profiling!

Lessons Learned from Early FIH/EFS Trials: Tricuspid Valve Repair Technologies

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Lessons Learned from Early FIH/EFS Trials: Mitral Valve Replacement and Repair Technologies

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

The TAVR Development Journey: Lessons Learned and Drivers of Success

Intermediate-Risk Studies II: Updates From SURTAVI

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Hypertension Treatment Targets Beyond the Kidneys

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content